Litigation Details for Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)

Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)

Docket		Date Filed	2019-01-31
Court	District Court, D. Delaware	Date Terminated	2022-04-19
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,566,729; 7,635,707; 7,767,700; 7,816,383; 7,910,610; 8,013,002; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,754,109; 8,778,947; 9,561,217
Link to Docket	External link to docket

Details for Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-31				External link to document
2019-01-30	31	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,566,729 B1; 7,635,707 B2; 7,767,700…2019 19 April 2022 1:19-cv-00202 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Summary of Litigation: Genentech, Inc. v. Sandoz, Inc. | 1:19-cv-00202

Last updated: February 4, 2026

This case involves patent infringement and validity claims concerning a biosimilar product. Genentech alleges that Sandoz’s biosimilar infringes on patents protecting its Oncology drug. Sandoz counters by asserting the patents are invalid and that it does not infringe any valid patent rights. The dispute centers on the legal standing of Genentech’s patent claims, the validity of the patents, and whether Sandoz’s biosimilar products infringe those patents.

Background

• Filed: February 25, 2019, in the District of Delaware.
• Patent(s) in dispute: Several patents related to the formulation, process, and manufacturing methods of the Roche (Genentech) drug.
• Sandoz’s product: A biosimilar to Genentech’s drug, intended for FDA approval under the Biologics Price Competition and Innovation Act (BPCIA).

Claims and Defenses

• Genentech’s Claims: Patent infringement of patents covering the drug's manufacturing process, formulation, and methods of use.
• Sandoz’s Defenses: Patent invalidity based on obviousness, lack of novelty, or non-infringement; and challenges to the patent’s enforceability.

Procedural History

• No preliminary injunction granted.
• The case includes extensive fact and expert discovery with multiple motions for summary judgment on patent validity and infringement issues.

Litigation Developments

• Patent invalidity motions: Sandoz has challenged the patents citing obviousness under 35 U.S.C. § 103, citing prior art references.
• Infringement Contentions: Genentech argues that Sandoz’s biosimilar infringes specific claims of its patents through the manufacturing process and product composition.
• Claim Construction: The court has issued claim construction orders clarifying key terms in the patent claims.
• Discovery Disputes: Both parties engaged in disputes over proprietary information and the scope of discovery, which the court has managed through protective orders.

Recent Proceedings

• Summary judgment motions are pending on patent validity and infringement issues.
• Trial dates are yet to be scheduled.
• The case may involve complex issues under the BPCIA, including patent dance provisions and biosimilar approval pathways.

Legal Analysis

• Patent Validity: Sandoz’s challenges rely heavily on obviousness and prior art references dating back decades. Patent validity will hinge on the court’s assessment of these references and the scope of the claims.
• Infringement: The argument is centered on whether Sandoz’s manufacturing process and the biosimilar product fall within the scope of the patent claims.
• Biosimilar Litigation Landscape: This case exemplifies the ongoing patent battleground under the BPCIA, with courts scrutinizing the scope of patent rights versus biosimilar entry.

Implications and Business Impact

• The outcome could influence biosimilar patent enforcement and carve out potential pathways for biosimilar manufacturers to navigate patent landscapes.
• A ruling invalidating patents could accelerate biosimilar market entry, impacting drug pricing and competition.
• A favorable ruling for Genentech would reinforce patent protections, potentially delaying biosimilar competition.

---

Key Takeaways

• The case involves a complex patent dispute under the BPCIA with patent validity and infringement at its core.
• Sandoz challenges the patents' novelty and obviousness; Genentech defends by asserting patent rights.
• The resolution could significantly affect biosimilar market dynamics and patent strategies.
• The litigation illustrates common issues in biosimilar patent litigation, including claim construction and prior art challenges.
• The case is likely to be a reference point for future biosimilar patent disputes.

---

FAQs

1. What patents are in dispute in this case?
   Genentech alleges infringement of patents related to the process, formulation, and manufacturing of its oncology biosimilar.

2. What defenses has Sandoz raised?
   Sandoz disputes the validity of the patents, citing obviousness and prior art, and denies infringing upon the patents through its biosimilar.

3. What is the significance of this case?
   It highlights issues in biosimilar patent law, including patent validity challenges, patent dance procedures under BPCIA, and the scope of patent protection.

4. Could this case affect biosimilar entry timelines?
   Yes, a ruling invalidating patents could allow faster biosimilar market entry, impacting pricing and competition.

5. What are the next procedural steps?
   Pending motions for summary judgment and claim construction, with trial dates possibly scheduled after resolution of dispositive motions.

---

References

[1] Docket in Genentech, Inc. v. Sandoz, Inc., No. 1:19-cv-00202 (D. Del., filed Feb. 25, 2019).